Shares of Fulcrum Therapeutics Inc. (FULC) have lost nearly 19% year-to-date and trade around $9.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing drugs for patients with genetically defined rare diseases in areas of high unmet medical need.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com